OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Sonneveld on the Potential of Quadruplet Therapy Regimens in Multiple Myeloma

August 22nd 2024

Pieter Sonneveld, MD, PhD, discusses the potential of quadruplet therapeutic regimens in the frontline management of multiple myeloma.

Dr Shouse on the Importance of NGS Testing in Follicular Lymphoma

August 22nd 2024

Geoffrey Shouse, DO, PhD, discusses the importance of performing next-generation sequencing in patients with follicular lymphoma.

Dr Mohty on the Potential Role of BCMA-Targeted Bispecific Antibodies in Myeloma

August 22nd 2024

Mohamad Mohty, MD, PhD, discusses the potential role of BCMA-targeted bispecific antibodies in myeloma.

Dr Li on the Clinical Implications of a Post Hoc Analysis of KEYNOTE-057 in BCG-Unresponsive NMIBC

August 22nd 2024

Roger Li, MD, discusses the implications of a post hoc analysis of the KEYNOTE-057 trial in BCG-unresponsive, high-risk non–muscle-invasive bladder cancer.

Dr Ravi on the Investigation of RCB Following ARPI Treatment in High-Risk Prostate Cancer

August 21st 2024

Praful K. Ravi, MB, BChir, MRCP, discusses the prognostic impact of residual cancer burden on long-term outcomes in high-risk localized prostate cancer.

Dr Reckamp on Emerging EGFR TKIs in EGFR Exon 20 Insertion+ NSCLC

August 21st 2024

Karen L. Reckamp, MD, MS, discusses emerging EGFR TKIs in EGFR Exon 20–Mutated NSCLC.

Dr Parikh on the Rationale for Adding ERAS-007 to the BEACON Regimen in BRAF V600E–Mutant mCRC

August 21st 2024

Aparna Parikh, MD, discusses the rationale for adding ERAS-007 to the BEACON regimen in BRAF V600E–mutated metastatic colorectal cancer.

Dr Tedeschi on the Initial Efficacy of Zanubrutinib Plus Venetoclax in Del 17p/TP53–Mutant CLL/SLL

August 21st 2024

Alessandra Tedeschi, MD, discusses the utility of zanubrutinib plus venetoclax in patients with CLL/SLL harboring deletion 17p and/or TP53 mutations.

Dr Kelly on the Importance of Testing For Genetic Abnormalities in GIST

August 21st 2024

Ciara Kelly, MBBCh, BAO, discusses the importance of genetic abnormality testing for patients with gastrointestinal stromal tumors.

Dr McGregor on the Future Implications of Ongoing Research in RCC

August 21st 2024

Bradley McGregor, MD, discusses the future implications of evolutions in the renal cell carcinoma treatment paradigm.

Dr Semaan on Liquid Biopsy vs Tissue Biopsy for Detecting Sarcomatoid RCC

August 20th 2024

Karl Semaan, MD, MSc, discusses the clinical advantages of liquid biopsy over tissue biopsies in detecting sarcomatoid renal cell carcinoma.

Dr Amanam on the Management of AEs Associated With JAK Inhibitors in Myelofibrosis

August 20th 2024

Idoroenyi Amanam, MD, discusses adverse effects associated with JAK inhibitors in myelofibrosis.

Dr Yee on Neoadjuvant Datopotamab Deruxtecan Plus Durvalumab in Early-Stage Breast Cancer

August 20th 2024

Douglas Yee, MD, discusses datopotamab deruxtecan and durvalumab in the neoadjuvant setting for early-stage breast cancer.

Dr Sonneveld on the FDA Approval of Subcutaneous Daratumumab Plus VRd in Myeloma

August 20th 2024

Pieter Sonneveld, MD, PhD, discusses the FDA approval of daratumumab plus VRd for select patients with newly diagnosed multiple myeloma.

Dr Tolaney on Frontline Treatment Approaches in HER2+ Breast Cancer

August 20th 2024

Sara M. Tolaney, MD, MPH, discusses standard frontline treatment approaches for patients with HER2-positive breast cancer.

Dr Subbiah on Outcomes With Larotrectinib in TRK Fusion–Positive Solid Tumors

August 20th 2024

Vivek Subbiah, MD, discusses data from the VICTORIA trial which evaluated treatment with larotrectinib in patients with TRK fusion–positive solid tumors.

Dr Shouse on AEs Associated With Targeted Therapies in FL

August 20th 2024

Geoffrey Shouse, DO, PhD, discusses adverse effects associated with targeted therapies used to treat patients with follicular lymphoma.

Dr McGregor on the Clinical Implications of the DAD-IO Trial in Urothelial Carcinoma

August 20th 2024

Bradley McGregor, MD, discusses the clinical implications of the DAD-IO trial in patients with metastatic urothelial carcinoma.

Dr Hernandez-Ilizaliturri on the Use of CAR T-Cell Therapy in R/R Multiple Myeloma

August 19th 2024

Francisco Hernandez-Ilizaliturri, MD, discusses the use of CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

Hood on the Association Between BRCA Mutations and Primary Tumor Location in PDAC

August 19th 2024

Ryan Hood, BA, discusses a study investigating the association between BRCA1/2 pathogenic variants and primary tumor location in pancreatic cancer.